Top

Published in:

01-02-2011 | Review

Amyloid imaging and memory change for prediction of cognitive impairment

Authors: Susan M Resnick, Jitka Sojkova

Published in: Alzheimer's Research & Therapy | Issue 1/2011

Abstract

PET radiotracers for in vivo measurement of β-amyloid (Aβ) deposition throughout the brain are contributing to early detection of the neuropathology associated with Alzheimer's disease and enhancing prediction of individuals most likely to develop cognitive impairment and dementia. However, the fact that 30 to 50% of cognitively normal older adults have varying but detectable levels of Aβ poses challenges and opportunities in using amyloid imaging in research and clinical applications. In this review, we summarize studies of the relationship between Aβ burden and cognitive status in impaired and unimpaired individuals and the relationship between Aβ burden and cognitive function. We conclude by operationalizing the way in which information on imaging-assessed Aβ burden and cognitive performance can be used jointly to improve prediction of clinical outcomes, to enhance understanding of the role of Aβ deposition in cognitive impairment, and to identify factors that promote cognitive resilience in the presence of Aβ.

Available only for authorised users

O'Brien RJ, Resnick SM, Zonderman AB, Ferrucci L, Crain BJ, Pletnikova O, Rudow G, Iacono D, Riudavets MA, Driscoll I, Price DL, Martin LJ, Troncoso JC: Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA). J Alzheimers Dis. 2009, 18: 665-675.PubMedCentralPubMed

Price JL, McKeel DW, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC: Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009, 30: 1026-1036. 10.1016/j.neurobiolaging.2009.04.002.PubMedCentralCrossRefPubMed

Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE: Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008, 65: 1509-1517. 10.1001/archneur.65.11.1509.PubMedCentralCrossRefPubMed

Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, Price JC, Reiman EM, Skovronsky D, Koeppe RA: The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010, 6: 221-229. 10.1016/j.jalz.2010.03.003.PubMedCentralCrossRefPubMed

Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC: [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006, 67: 446-452. 10.1212/01.wnl.0000228230.26044.a4.CrossRefPubMed

Resnick SM, Sojkova J, Zhou Y, An Y, Ye W, Holt DP, Dannals RF, Mathis CA, Klunk WE, Ferrucci L, Kraut MA, Wong DF: Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology. 2010, 74: 807-815. 10.1212/WNL.0b013e3181d3e3e9.PubMedCentralCrossRefPubMed

Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL: Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010, 31: 1275-1283. 10.1016/j.neurobiolaging.2010.04.007.CrossRefPubMed

Hyman BT: The neuropathological diagnosis of Alzheimer's disease: clinical-pathological studies. Neurobiol Aging. 1997, 18 (4 Suppl): S27-32. 10.1016/S0197-4580(97)00066-3.CrossRefPubMed

Morris JC, Storandt M, McKeel DW, Rubin EH, Price JL, Grant EA, Berg L: Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. Neurology. 1996, 46: 707-719.CrossRefPubMed

10.

Morris JC: Mild cognitive impairment and preclinical Alzheimer's disease. Geriatrics. 2005, 9-14. Suppl

11.

Driscoll I, Resnick SM, Troncoso JC, An Y, O'Brien R, Zonderman AB: Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly. Ann Neurol. 2006, 60: 688-695. 10.1002/ana.21031.CrossRefPubMed

12.

Galvin JE, Powlishta KK, Wilkins K, McKeel DW, Xiong C, Grant E, Storandt M, Morris JC: Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol. 2005, 62: 758-765. 10.1001/archneur.62.5.758.CrossRefPubMed

13.

Petersen RC, Morris JC: Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol. 2005, 62: 1160-1163. 10.1001/archneur.62.7.1160. discussion 1167CrossRefPubMed

14.

Sojkova J, Resnick SM: In vivo human amyloid imaging. Curr Alzheimer Res. 2011,

15.

Klunk WE, Mathis CA: Amyloid imaging and (what is normal?) aging. Imaging the Aging Brain. Edited by: Jagust WDE. 2009, Oxford, USA: Oxford University Press

16.

Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC, Alzheimer's Disease Neuroimaging Initiative: Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009, 132: 1355-1365. 10.1093/brain/awp062.PubMedCentralCrossRefPubMed

17.

Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, Hasselbalch S, Law I, Andersen A, Korner A, Minthon L, Garraux G, Nelissen N, Bormans G, Buckley C, Owenius R, Thurfjell L, Farrar G, Brooks DJ: (18) F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol. 2010, 68: 319-329. 10.1002/ana.22068.CrossRefPubMed

18.

Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Nandi A, Brasić JR, Ye W, Hilton J, Lyketsos C, Kung HF, Joshi AD, Skovronsky DM, Pontecorvo MJ: In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010, 51: 913-920. 10.2967/jnumed.109.069088.PubMedCentralCrossRefPubMed

19.

Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung MP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Lehman L, Lindemann S, Dinkelborg LM, Masters CL, Villemagne VL: Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008, 7: 129-135. 10.1016/S1474-4422(08)70001-2.CrossRefPubMed

20.

Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR: PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006, 355: 2652-2663. 10.1056/NEJMoa054625.CrossRefPubMed

21.

Tolboom N, Yaqub M, van der Flier WM, Boellaard R, Luurtsema G, Windhorst AD, Barkhof F, Scheltens P, Lammertsma AA, van Berckel BN: Detection of Alzheimer pathology In vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med. 2009, 50: 191-197. 10.2967/jnumed.108.056499.CrossRefPubMed

22.

Shin J, Lee SY, Kim SJ, Kim SH, Cho SJ, Kim YB: Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG. Neuroimage. 2010, 52: 488-496. 10.1016/j.neuroimage.2010.04.013.CrossRefPubMed

23.

Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Langstrom B, Nordberg A: PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008, 29: 1456-1465. 10.1016/j.neurobiolaging.2007.03.029.CrossRefPubMed

24.

Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ: Conversion of amyloid positive and negative MCI to AD over 3 years. An 11C-PIB PET study. Neurology. 2009, 73: 754-760. 10.1212/WNL.0b013e3181b23564.PubMedCentralCrossRefPubMed

25.

Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, Aizenstein HJ, Cohen AD, Weissfeld LA, Mathis CA, Klunk WE, De-Kosky ST: Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009, 65: 557-568. 10.1002/ana.21598.PubMedCentralCrossRefPubMed

26.

Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, DeSanti S, Kemppainen N, Någren K, Kim BC, Tsui W, de Leon MJ: Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2008, 35: 2169-2181. 10.1007/s00259-008-0833-y.PubMedCentralCrossRefPubMed

27.

Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA: Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005, 25: 1528-1547. 10.1038/sj.jcbfm.9600146.CrossRefPubMed

28.

Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O'Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL: Imaging beta-amyloid burden in aging and dementia. Neurology. 2007, 68: 1718-1725. 10.1212/01.wnl.0000261919.22630.ea.CrossRefPubMed

29.

Lowe VJ, Kemp BJ, Jack CR, Senjem M, Weigand S, Shiung M, Smith G, Knopman D, Boeve B, Mullan B, Petersen RC: Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med. 2009, 50: 878-886. 10.2967/jnumed.108.058529.PubMedCentralCrossRefPubMed

30.

Rosen RF, Ciliax BJ, Wingo TS, Gearing M, Dooyema J, Lah JJ, Ghiso JA, Levine H, Walker LC: Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease. Acta Neuropathol. 2010, 119: 221-233. 10.1007/s00401-009-0583-3.PubMedCentralCrossRefPubMed

31.

Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA: APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010, 67: 122-131. 10.1002/ana.21843.PubMedCentralCrossRefPubMed

32.

Stern Y: What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc. 2002, 8: 448-460. 10.1017/S1355617702813248.CrossRefPubMed

33.

Rentz DM, Locascio JJ, Becker JA, Moran EK, Eng E, Buckner RL, Sperling RA, Johnson KA: Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol. 2010, 67: 353-364. 10.1001/archneurol.2010.19.PubMedCentralPubMed

34.

Chételat G, Villemagne VL, Pike KE, Baron JC, Bourgeat P, Jones G, Faux NG, Ellis KA, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC, Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group: Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain. 2010, 133: 3349-3358.CrossRefPubMed

35.

Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC: Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007, 130: 2837-2844. 10.1093/brain/awm238.CrossRefPubMed

36.

Tolboom N, van der Flier WM, Yaqub M, Koene T, Boellaard R, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN: Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment. Neurology. 2009, 73: 2079-2085. 10.1212/WNL.0b013e3181c679cc.CrossRefPubMed

37.

Forsberg A, Almkvist O, Engler H, Wall A, Langstrom B, Nordberg A: High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res. 2010, 7: 56-66. 10.2174/156720510790274446.CrossRefPubMed

38.

Roe CM, Mintun MA, D'Angelo G, Xiong C, Grant EA, Morris JC: Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol. 2008, 65: 1467-1471. 10.1001/archneur.65.11.1467.PubMedCentralCrossRefPubMed

39.

Braskie MN, Klunder AD, Hayashi KM, Protas H, Kepe V, Miller KJ, Huang SC, Barrio JR, Ercoli LM, Siddarth P, Satyamurthy N, Liu J, Toga AW, Bookheimer SY, Small GW, Thompson PM: Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease. Neurobiol Aging. 2010, 31: 1669-1678. 10.1016/j.neurobiolaging.2008.09.012.PubMedCentralCrossRefPubMed

40.

Furst AJ, Rabinovici GD, Rostomian AH, Steed T, Alkalay A, Racine C, Miller BL, Jagust WJ: Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol Aging. 2010,

41.

Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ: Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009, 132: 1310-1323. 10.1093/brain/awn320.PubMedCentralCrossRefPubMed

42.

Storandt M, Mintun MA, Head D, Morris JC: Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol. 2009, 66: 1476-1481. 10.1001/archneurol.2009.272.PubMedCentralCrossRefPubMed

43.

Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, Ackermann U, Cowie TF, Currie J, Chan SG, Jones G, Tochon-Danguy H, O'Keefe G, Masters CL, Rowe CC: Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia. 2008, 46: 1688-1697. 10.1016/j.neuropsychologia.2008.02.008.CrossRefPubMed

44.

Koivunen J, Pirttilä T, Kemppainen N, Aalto S, Herukka SK, Jauhianen AM, Hänninen T, Hallikainen M, Någren K, Rinne JO, Soininen H: PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord. 2008, 26: 378-383. 10.1159/000163927.CrossRefPubMed

45.

Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA: Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009, 66: 1469-1475. 10.1001/archneurol.2009.269.PubMedCentralCrossRefPubMed

46.

Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, Smith EE, Rosand J, Rentz DM, Klunk WE, Mathis CA, Price JC, Dekosky ST, Fischman AJ, Greenberg SM: Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007, 62: 229-234. 10.1002/ana.21164.CrossRefPubMed

47.

Davatzikos C, Xu F, An Y, Fan Y, Resnick SM: Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. Brain. 2009, 132: 2026-2035. 10.1093/brain/awp091.PubMedCentralCrossRefPubMed

48.

Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M: 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010, 9: 363-372. 10.1016/S1474-4422(10)70043-0.CrossRefPubMed

49.

Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ: Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9: 119-128. 10.1016/S1474-4422(09)70299-6.PubMedCentralCrossRefPubMed

50.

Iacono D, O'Brien R, Resnick SM, Zonderman AB, Pletnikova O, Rudow G, An Y, West MJ, Crain B, Troncoso JC: Neuronal hypertrophy in asymptomatic Alzheimer disease. J Neuropathol Exp Neurol. 2008, 67: 578-589. 10.1097/NEN.0b013e3181772794.PubMedCentralCrossRefPubMed

51.

Riudavets MA, Iacono D, Resnick SM, O'Brien R, Zonderman AB, Martin LJ, Rudow G, Pletnikova O, Troncoso JC: Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons. Neurobiol Aging. 2007, 28: 1484-1492. 10.1016/j.neurobiolaging.2007.05.005.PubMedCentralCrossRefPubMed

52.

Aisen PS: Predictors of progression in the ADNI-MCI cohort. Alzheimers Dementia. 2010, 6: S63-10.1016/j.jalz.2010.05.180.CrossRef

53.

Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM: Inverse relation between In vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006, 59: 512-519. 10.1002/ana.20730.CrossRefPubMed

54.

Grimmer T, Henriksen G, Wester HJ, Forstl H, Klunk WE, Mathis CA, Kurz A, Drzezga A: Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. Neurobiol Aging. 2009, 30: 1902-1909. 10.1016/j.neurobiolaging.2008.01.016.CrossRefPubMed

Title: Amyloid imaging and memory change for prediction of cognitive impairment
Authors: Susan M Resnick
Jitka Sojkova
Publication date: 01-02-2011
Publisher: BioMed Central
Published in: Alzheimer's Research & Therapy / Issue 1/2011
Electronic ISSN: 1758-9193
DOI: https://doi.org/10.1186/alzrt62

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Amyloid imaging and memory change for prediction of cognitive impairment

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study

Should EOAD patients be included in clinical trials?

Can aerobic exercise protect against dementia?

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease

What was lost in translation in the DHA trial is whom you should intend to treat